Valitor

[Valitor @valitorbio]

#ICYMI: Watch the latest video from @RetinalPhys where Director of Development, Livia Wilz Brier, Ph.D., gives an overview of her recent #ARVO2026 oral presentation highlighting the potential of VLTR-559 to treat Wet AMD.

Watch the full video here: https://t.co/8viglgihtr

[Valitor @valitorbio]

We presented preclinical data demonstrating the superior durability, efficacy & safety profile of VLTR-559 to treat wet-AMD at #ARVO2026. Data reinforces the potential of VLTR-559 to transform the treatment landscape & reduce treatment burden for patients.
https://t.co/9IE7jALRSt

[Valitor @valitorbio]

Dir. of Development, Livia Brier, Ph.D., will discuss the potential of VLTR-559 to treatment wet AMD, in an oral presentation at the ARVO Annual Meeting on Sun, May 3, 2026, at 3:30 p.m. MT.

Be sure to check out the presentation if you’re attending the meeting. #ARVO2026

[Valitor @valitorbio]

Chief Scientific Officer, Wesley Jackson, Ph.D., will join other industry experts in a panel discussion at Eyecelerator @ ARVO 2026 on Friday, May 1, 2026 at 2:50 p.m. MT.

Check out the panel discussion if you’re in attendance.

Learn more: https://t.co/kzGgOBL3Af

[Valitor @valitorbio]

CEO Gregory D. Kunst will share a company overview describing our platform technology and pipeline in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Mon, Apr 13, 2026 at 2:15 p.m. ET. Listen to the live or archived discussion:https://t.co/bCTuLGL5Xd

[Valitor @valitorbio]

We’re excited to announce that a preclinical abstract highlighting the potential of VLTR-559 to treat wet AMD, has been accepted for oral presentation at the ARVO Annual Meeting taking place May 3-7,2026 in Denver, CO.

Learn more: https://t.co/JuaZewYYgE

[Valitor @valitorbio]

On Tues, Feb 24th at 2:00 p.m. PT, CEO Greg Kunst will present a company overview & host investor one-on-one meetings at the Biocom Global Partnering and Investor Conference. If you will be attending the conference, we welcome the opportunity to connect!
https://t.co/HUaFWKRk9g

[Valitor @valitorbio]

During #AMD & #LowVisionAwarenessMonth, we recognize the millions living with visual impairment.
We’re committed to advancing our MVP technology platform for vision-threatening diseases, including wet #AMD. Learn more about vision rehabilitation resources: https://t.co/3WsezZk61f

[Valitor @valitorbio]

Chief Scientific Officer, Wesley Jackson, Ph.D., will join other ophthalmology experts in a panel discussion and a seminar at the 4th Annual Ophthalmic Drug Delivery Summit taking place Jan 27-29, 2026, in San Francisco, CA. Learn more: https://t.co/ycuz7HIFDd

[Valitor @valitorbio]

Season’s Greetings from Valitor!

We’re thankful for the continued support as we pursue innovative ophthalmic medicines aimed at improving vision and transforming patient care.

Wishing you a joyful holiday season and a bright year ahead.

#HappyHolidays

[Valitor @valitorbio]

CEO Gregory D. Kunst will join fellow ophthalmic drug development leaders at BTIG’s 5th Annual Ophthalmology Day on Mon, Dec 1, 2025, to discuss emerging innovation in ophthalmology. Greg will also be available for one-on-one investor meetings.

[Valitor @valitorbio]

Valitor CEO Gregory D. Kunst, will review preclinical data highlighting the potential of VLTR-559 in a presentation at the 15th Annual @OISTWEETS Ophthalmology Innovation Summit taking place Nov 21-22, 2025 in San Diego, CA.

Learn more: https://t.co/YfOIMFubqv

#OIS2025

[Valitor @valitorbio]

At #Eyecelerator, we shared preclinical data showing VLTR-559 supports potential 6-month dosing for wet AMD, with a longer ocular half-life and sustained retinal exposure vs current anti-VEGF therapies.

Learn more: https://t.co/UKt7NQkfQU

[Valitor @valitorbio]

We’re excited to welcome Gregory D. Kunst as CEO of Valitor!
A seasoned leader in biotech and ophthalmology, Greg will be instrumental as we advance VLTR-559, our long-acting anti-VEGF therapy for wet AMD, into clinical studies.

https://t.co/PVz2Aqbjlm

[Valitor @valitorbio]

This #VisionAwarenessMonth, we’re reminding everyone that early detection is key to protecting sight.
At Valitor, we’re engineering the next generation of ophthalmic medicines to potentially help preserve and restore vision.

#EyeHealth #Ophthalmology

[Valitor @valitorbio]

President and CSO, Wesley Jackson, Ph.D., will present new preclinical data highlighting the potential of VLTR-559 to treat wet age-related macular degeneration (AMD), at the @Eyecelerator @aao_ophth annual meeting Thurs, Oct 16, 2025 at 1:15 p.m. ET.

[Valitor @valitorbio]

At the Ophthalmology Futures Retina Forum, we presented new in vivo safety data which build on a series of highly promising results demonstrating VLTR-559 has the capacity to significantly redefine the treatment regimen for wet AMD. Read the PR: https://t.co/BTMdWzbcrz

[Valitor @valitorbio]

On #WomensEqualityDay, we celebrate the women scientists driving innovation in ophthalmology at Valitor.

Their work developing long-acting retinal medicines is transforming vision care and inspiring the next generation.

#WomenInScience #STEM
#OphthalmologyInnovation

[Valitor @valitorbio]

We are excited for the unveiling of our NHP data for VLTR-559, a long-acting anti-VEGF therapy for the treatment of wet AMD, at the Ophthalmology Futures Retina Forum and Euretina Conference. If you are attending, reach out to meet. Read PR: https://t.co/4PxwbyDHkm

[Valitor @valitorbio]

At #OISRetina President & CSO Wesley Jackson, Ph.D., shared new data on VLTR-559, a long-acting treatment for wet AMD, showing prolonged ocular retention with durable high potency. Results highlight potential to improve outcomes & lower costs for patients. https://t.co/NY9ucxmNVw